The House resumed from May 8 consideration of the motion that Bill C-265, An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access), be read the second time and referred to a committee.
In the House of Commons on June 10th, 2026. See this statement in context.